MATWIN (Maturation and Accelerating Translation With Industry) is a French platform wholly owned by Unicancer, exclusively dedicated to supporting innovation in oncology. Its mission is to assist scientists and entrepreneurs in evaluating and optimizing opportunities to translate their research into concrete solutions for patients.
For over 15 years, MATWIN has implemented various initiatives aimed at supporting the development of innovative projects specifically focused on combating cancer. These efforts are grounded in a longstanding partnership with approximately 15 international laboratories seeking to source high-potential, innovative projects by leveraging the excellence of French and European research in this field.
MATWIN’s activities revolve around 3 main actions:
- A support program to accelerate the development of innovative projects originating from academia or early-stage startups (the MATWIN program),
- An annual European partnering event dedicated to oncology (MEET2WIN),
- Coordination of a consortium bringing together 14 partner organizations working to stimulate entrepreneurship in the fight against cancer (OncoSTART).
Regarding the support program, the objective is to select and assist innovative oncology research projects with high potential for technology transfer, offering tailored support over a 3- to 6-month period. This includes access to expertise, coaching/mentoring, and a network of partners capable of fostering their growth.
Over 15 years of activity, some key figures highlight MATWIN’s achievements:
300+ projects supported through the accelerator program
50+ startups created post-support
50+ projects transferred to external partners
30+ clinical trials launched between 2017 and 2022
9 MEET2WIN conventions (2 800 participants, 6 000 meetings)
200+ entrepreneurs trained via OncoSTART
2024 data
